Future Opportunities in Drug Development: American Society for Clinical Pharmacology and Therapeutics Pharmacometrics and Pharmacokinetics Community Vision

Significant opportunities are arising for clinical pharmacology to enhance drug development by leveraging rapidly evolving innovations within biomedical research. Scanning the scientific landscape, current and upcoming innovations can be summarized into three major categories: new therapeutic modalities, expanding data types, and new analytical tools (Figure 1). The Pharmacometrics and Pharmacokinetics (PMK) community within the American Society for Clinical Pharmacology and Therapeutics (ASCPT) aims to foster collaboration, communication, and scientific advancement across these areas of innovation addressing both the opportunities and their associated challenges. The goal of this perspective is to catalyze scientific collaboration across the broad range of ASCPT networks and communities focused on addressing opportunities and challenges for the field of clinical pharmacology and beyond.

Automated summary

Significant opportunities are emerging for clinical pharmacology to improve drug development through the use of rapidly evolving innovations in biomedical research. Current and upcoming innovations in the field can be classified into three major categories: new therapeutic modalities, expanding data types, and new analytical tools. The Pharmacometrics and Pharmacokinetics (PMK) community within the American Society for Clinical Pharmacology and Therapeutics (ASCPT) aims to facilitate collaboration, communication, and scientific advancement in these areas, addressing both the opportunities and challenges they present. This perspective seeks to encourage scientific collaboration across a wide range of ASCPT networks and communities, focusing on opportunities and challenges in the field of clinical pharmacology and beyond.